Resource Summary Report

Generated by FDI Lab - SciCrunch.org on May 29, 2025

p44/42 MAPK (Erk1/2) Antibody

RRID:AB_330744
Type: Antibody

Proper Citation

(Cell Signaling Technology Cat# 9102, RRID:AB_330744)

Antibody Information

URL: http://antibodyregistry.org/AB_330744

Proper Citation: (Cell Signaling Technology Cat# 9102, RRID:AB_330744)

Target Antigen: p44/42 MAPK (Erk1/2)

Host Organism: rabbit

Clonality: polyclonal

Comments: Applications: WB, IP
Consolidation on 9/2016: AB_823494, AB_10695746.
Info: Independent validation by the NYU Lagone was performed for: IHC. This antibody was found to have the following characteristics: Functional in human:TRUE, NonFunctional in human:FALSE, Functional in animal:FALSE, NonFunctional in animal:FALSE

Antibody Name: p44/42 MAPK (Erk1/2) Antibody

Description: This polyclonal targets p44/42 MAPK (Erk1/2)

Target Organism: monkey, rat, hamster, mink, pig, yeastfungi, mouse, zebrafishfish, bovine, zebrafish, human, s. cerevisiae

Antibody ID: AB_330744

Vendor: Cell Signaling Technology

Catalog Number: 9102

Alternative Catalog Numbers: 9102S, 9102L

Record Creation Time: 20231110T075901+0000

Record Last Update: 20241115T052410+0000

Ratings and Alerts

- Independent validation by the NYU Lagone was performed for: IHC. This antibody was found to have the following characteristics: Functional in human:TRUE, NonFunctional in human:FALSE, Functional in animal:FALSE, NonFunctional in animal:FALSE - NYU Langone's Center for Biospecimen Research and Development https://med.nyu.edu/research/scientific-cores-shared-resources/center-biospecimen-research-development

No alerts have been found for p44/42 MAPK (Erk1/2) Antibody.

Data and Source Information

Source: Antibody Registry

Usage and Citation Metrics

We found 609 mentions in open access literature.

Listed below are recent publications. The full list is available at FDI Lab - SciCrunch.org.

Lobete M, et al. (2024) A methodology to globally assess ectodomain shedding using soluble fractions from the mouse brain. Frontiers in psychiatry, 15, 1367526.

Ahmed MR, et al. (2024) Arrestin-3-assisted activation of JNK3 mediates dopaminergic behavioral sensitization. Cell reports. Medicine, 5(7), 101623.

Goto Y, et al. (2024) A Kinome-Wide Synthetic Lethal CRISPR/Cas9 Screen Reveals That mTOR Inhibition Prevents Adaptive Resistance to CDK4/CDK6 Blockade in HNSCC. Cancer research communications, 4(7), 1850.

Becker JH, et al. (2024) Targeting BCL2 with Venetoclax Enhances the Efficacy of the KRASG12D Inhibitor MRTX1133 in Pancreatic Cancer. Cancer research, 84(21), 3629.

Park SH, et al. (2024) Gestodene, a novel positive allosteric modulator of PAR1, enhances PAR1-mediated human platelet aggregation. Frontiers in pharmacology, 15, 1430548.

Alateeq R, et al. (2024) Apocynin Prevents Cigarette Smoke-Induced Anxiety-Like Behavior and Preserves Microglial Profiles in Male Mice. Antioxidants (Basel, Switzerland), 13(7).

Lao-Peregrin C, et al. (2024) Synaptic plasticity via receptor tyrosine kinase/G-protein-coupled receptor crosstalk. Cell reports, 43(1), 113595.

Tong X, et al. (2024) Adeno-to-squamous transition drives resistance to KRAS inhibition in LKB1 mutant lung cancer. Cancer cell, 42(3), 413.

Ben S, et al. (2024) Microglia-endothelial cross-talk regulates diabetes-induced retinal vascular dysfunction through remodeling inflammatory microenvironment. iScience, 27(3), 109145.

Li GX, et al. (2024) Comprehensive proteogenomic characterization of rare kidney tumors. Cell reports. Medicine, 5(5), 101547.

Bai Y, et al. (2024) Trans-omic analysis reveals opposite metabolic dysregulation between feeding and fasting in liver associated with obesity. iScience, 27(3), 109121.

Kalnytska O, et al. (2024) SORCS2 activity in pancreatic ?-cells safeguards insulin granule formation and release from glucose-stressed ?-cells. iScience, 27(1), 108725.

Becattini B, et al. (2024) Adipocyte PI3K links adipostasis with baseline insulin secretion at fasting through an adipoincretin effect. Cell reports, 43(5), 114132.

Roper N, et al. (2024) Functional Heterogeneity in MET Pathway Activation in PDX Models of Osimertinib-resistant EGFR-driven Lung Cancer. Cancer research communications, 4(2), 337.

Lee S, et al. (2024) B7H6 is the predominant activating ligand driving natural killer cell-mediated killing in patients with liquid tumours: evidence from clinical, in silico, in vitro, and in vivo studies. EBioMedicine, 110, 105459.

Lu Y, et al. (2024) Activation of Bradykinin B2 Receptors in Astrocytes Stimulates the Release of Leukemia Inhibitory Factor for Autocrine and Paracrine Signaling. International journal of molecular sciences, 25(23).

Jacob J, et al. (2024) Antibody-Drug Conjugates Targeting the EGFR Ligand Epiregulin Elicit Robust Anti-Tumor Activity in Colorectal Cancer. bioRxiv : the preprint server for biology.

Sreekumar A, et al. (2024) B3GALT6 promotes dormant breast cancer cell survival and recurrence by enabling heparan sulfate-mediated FGF signaling. Cancer cell, 42(1), 52.

Wang C, et al. (2024) SPOCK2 modulates neuropathic pain by interacting with MT1-MMP to regulate astrocytic MMP-2 activation in rats with chronic constriction injury. Journal of neuroinflammation, 21(1), 57.

Cerutti C, et al. (2024) IQGAP1 and NWASP promote human cancer cell dissemination and metastasis by regulating ?1-integrin via FAK and MRTF/SRF. Cell reports, 43(4), 113989.